ClouDr Group's gross profit for the
six
months ended in Dec. 2023 was HK$477 Mil. ClouDr Group's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was HK$995 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. ClouDr Group's gross profit for the
six
months ended in Dec. 2023 was HK$477 Mil. ClouDr Group's Revenue for the
six
months ended in Dec. 2023 was HK$2,065 Mil. Therefore, ClouDr Group's Gross Margin % for the quarter that ended in Dec. 2023 was 23.08%.
ClouDr Group had a gross margin of 23.08% for the quarter that ended in Dec. 2023 => Competition eroding margins
During the past 5 years, the highestGross Margin % of ClouDr Group was 32.45%. The lowest was 11.74%. And the median was 26.51%.
ClouDr Group Gross Profit Historical Data
The historical data trend for ClouDr Group's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ClouDr Group's Gross Profit
For the Medical Distribution subindustry, ClouDr Group's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group's Gross Profit Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's Gross Profit distribution charts can be found below:
* The bar in red indicates where ClouDr Group's Gross Profit falls into.
ClouDr Group Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
ClouDr Group's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$995 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ClouDr Group (HKSE:09955) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ClouDr Group had a gross margin of 23.08% for the quarter that ended in Dec. 2023 => Competition eroding margins
ClouDr Group Gross Profit Related Terms
Thank you for viewing the detailed overview of ClouDr Group's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09955 has been successfully added to your